Israel Englander Gilead Sciences, Inc. Call Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $3.94 Million - $4.96 Million	-59,100 Reduced 9.45%	566,000 $47.4 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $10.3 Million - $11.9 Million	-163,400 Reduced 20.72%	625,100 $42.9 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $19.2 Million - $23.5 Million	-268,800 Reduced 25.42%	788,500 $57.8 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $6.02 Million - $6.82 Million	82,100 Added 8.42%	1,057,300 $85.7 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $12.2 Million - $13.9 Million	-160,600 Reduced 14.14%	975,200 $75.2 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $12.9 Million - $14.7 Million	167,200 Added 17.26%	1,135,800 $94.2 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $72.8 Million - $104 Million	-1,167,500 Reduced 54.66%	968,600 $83.2 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $46.9 Million - $53.5 Million	787,000 Added 58.34%	2,136,100 $132 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.